CN Patent

CN102946875A — 组合疗法

Assigned to Boehringer Ingelheim International GmbH · Expires 2013-02-27 · 13y expired

What this patent protects

本发明涉及治疗和/或预防代谢疾病的方法，其包括组合给药GLP-1受体激动剂和DPP-4抑制剂。

USPTO Abstract

本发明涉及治疗和/或预防代谢疾病的方法，其包括组合给药GLP-1受体激动剂和DPP-4抑制剂。

Drugs covered by this patent

Patent Metadata

Patent number
CN102946875A
Jurisdiction
CN
Classification
—
Expires
2013-02-27
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.